94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Neurol.
Sec. Neuroepidemiology
Volume 16 - 2025 | doi: 10.3389/fneur.2025.1395798
Assessment of causality in associations between serum adiponectin and the risk of Alzheimer's disease and Parkinson's disease: A Mendelian Randomization Study
Provisionally accepted- People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi Zhuang Region, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Until recently, the association between circulating adiponectin (ADPN) levels and the risk of Alzheimer's disease (AD) and Parkinson's disease (PD) was unclear.Methods: We utilized public data from the IEU GWAS database for two-sample bidirectional Mendelian randomization (MR) analysis and multiple sensitivity analyses. MR analysis was performed on the aggregated data utilizing the Genetic risk score (GRS) as an instrumental variable Results: The MR analyses revealed no significant causal association between the genetically determined ADPN and AD (ORIVW = 0.852, 95% confidence interval [CI]: 0.586-1.117, P = 0.235) or PD (ORIVW = 0.830, 95% CI: 0.780-1.156, P = 0.606) risk. In the opposite direction, AD and PD also did not demonstrate any causal association with ADPN. GRS approach yielded similar results (P>0.05).But, exhibited a negative correlation with interleukin 1 (IL1, βIVW = -0.31; 95% CI: -0.55 to -0.07, P = 0.011). The Cochrane test and MR-PRESSO analysis revealed no evidence of pleiotropy in MR results.Conclusions: Our findings yielded no evidence to substantiate a causal relationship between ADPN levels and the risk of AD and PD, or vice versa. However, elevated levels of ADPN may correlate with lower levels of IL1.
Keywords: Adiponectin, Alzheimer's disease, Parkinson's disease, Mendelian randomization, Neurodegenerative Diseases
Received: 05 Mar 2024; Accepted: 11 Apr 2025.
Copyright: © 2025 Lin, Lei, Liang, Huang, Ding, Pan, Yang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Wei Li, People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi Zhuang Region, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.